Market Place
Sourcing Support
First-in-Class Investigational SX-682 Demonstrates Efficacy in Patients
09 Dec 2022 //
PRNEWSWIRE
Syntrix Completes Initial SX-682 Dosing in Broad Phase 1/2 Cancer Trial
26 Oct 2020 //
PRNEWSWIRE
Syntrix Discovers Desmetramadol is G-Protein Biased Opioid Receptor Agonist
04 Feb 2020 //
PR NEWSWIRE
Syntrix Pharmaceuticals to Present +ve Desmetramadol Trial Results at the 2019
31 Oct 2019 //
PR NEWSWIRE
Syntrix Pharmaceuticals` Positive Double-Blind Clinical Trials of Desmetramadol
04 Jun 2019 //
PR NEWSWIRE
Syntrix Wins $3.4M NIH Grant to Conduct Phase 1/2 Trial of SX-682 in Myelodysplastic Syndrome
04 Feb 2019 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.